Clinical Data Supporting CAR T in Earlier Lines: Updates From the CARTITUDE-1, CARTITUDE-4, and KarMMa-3 Trials
Panelists discuss how clinical trial data from CARTITUDE-1, CARTITUDE-4, and KarMMa-3 demonstrate the efficacy of CAR T therapies cilta-cel and ide-cel in multiple myeloma, comparing their real-world outcomes and considering patient-specific factors for treatment selection.
EP: 1.A High-Risk Myeloma Patient’s Path to CAR T: Personal and Clinical Perspectives
EP: 2.Behind the Scenes: Patient Education and Decision-Making for CAR T
Now Viewing
EP: 3.Clinical Data Supporting CAR T in Earlier Lines: Updates From the CARTITUDE-1, CARTITUDE-4, and KarMMa-3 Trials
EP: 4.The Real-World Logistics of CAR T Therapy: Financial and Practical Considerations
Video content above is prompted by the following:
- Let’s start by discussing the treatment landscape and data with CAR T therapy in multiple myeloma. Please highlight pivotal data:
- CARTITUDE-1/CARTITUDE-4
- KarMMa-3
- In which patients do you consider cilta-cel vs ide-cel? Has real-world practice reflected efficacy and safety data from these trials?
Recent Videos
Related Content
